2025-09-15 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data.  The report is structured to first present the raw numbers, followed by concise analysis.

**Report on Johnson & Johnson (JNJ)**

Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 30.07%
*   **VOO Cumulative Return:** 104.48%
*   **Relative Divergence:**
    *   Current Divergence: -70.1
    *   Max: 13.9, Min: -77.9
    *   Relative Divergence (% of Range): 8.5

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The relative divergence indicates JNJ is currently near the bottom of its historical underperformance range compared to the S&P 500.

* **Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.1% | -1.0% | -0.0 | 336.5 |
| 2016-2018  | 8.0% | 56.6% | -10.0% | 0.0 | 310.8 |
| 2017-2019  | 18.0% | 56.6% | -12.0% | 0.7 | 351.3 |
| 2018-2020  | 12.0% | 59.2% | -8.0% | 0.3 | 379.0 |
| 2019-2021  | 32.0% | 59.6% | -16.0% | 0.2 | 412.0 |
| 2020-2022  | 7.0% | 61.4% | 5.0% | 0.2 | 425.4 |
| 2021-2023  | -15.0% | 61.4% | -33.0% | 0.4 | 377.5 |
| 2022-2024  | -35.0% | 61.4% | -61.0% | 0.3 | 348.3 |
| 2023-2025  | 3.0% | 70.1% | -53.0% | 0.2 | 428.8 |

**Analysis:** This table shows JNJ's performance metrics over rolling three-year periods.  Key observations:

*   **CAGR:** Varies significantly, with negative values in recent periods (2021-2025).
*   **MDD:**  Maximum Drawdown is consistently high, indicating significant risk of loss.
*   **Alpha:** Consistently negative, indicating underperformance relative to its benchmark (risk-adjusted).  The recent figures are particularly poor.
*   **Beta:** Generally low, suggesting JNJ is less volatile than the overall market.
*   **Cap(B):**  Market capitalization generally increased, but has experienced some decreases.

**2. Recent Price Action**

*   **Current Price:** 178.06
*   **Previous Close:** 178.5
*   **Change:** -0.25
*   **5-day Moving Average:** 177.488
*   **20-day Moving Average:** 177.582
*   **60-day Moving Average:** 167.3978

**Analysis:** The current price is slightly down from the previous close. The 5-day and 20-day moving averages are very close, suggesting a period of price consolidation.  The 60-day moving average is significantly lower, suggesting an overall upward trend over the past couple of months, but recent movement may be slowing down.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 45.70 (Neutral)
*   **PPO:** -0.3133 (Bearish Signal)
*   **Hybrid Signal:** cash_67%_Sell 4.0% of holdings (13 shares - Caution - MRI:0.34) (Cash Ratio: 67% on 2025-09-03)
*   **Delta_Previous_Relative_Divergence (20-day):** -3.3 (Short-term decline)
*   **Expected Return (%):** -347.6 (Significant underperformance vs. S&P 500 over 2+ year horizon)

**Analysis:**  The MRI suggests a low-risk market environment. However, the RSI is neutral, and the PPO indicates bearish momentum. The hybrid signal suggests reducing holdings and increasing cash. The negative change in relative divergence confirms a short-term downward trend.  The dramatically negative expected return is a major red flag. The slight negative change from previous close does indicate a notable short-term impact.

**4. Recent News & Significant Events**

*   **[2025-09-13] Jim Cramer Says Procter & Gamble Stock is “Still Way Too High” (Insider Monkey)**
*   **[2025-09-13] How Strong Is Johnson & Johnson’s Value After FDA Nod for New Drug in 2025? (Simply Wall St.)**
*   **[2025-09-12] Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most. (Barrons.com)**
*   **[2025-09-12] JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)**
*   **[2025-09-12] AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock (Zacks)**
*   **[2025-09-12] Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? (Zacks)**

**Analysis:** The news is mixed.  The FDA approval is a positive catalyst for JNJ. The article on prescription drug ads introduces uncertainty. The EU approval application is also positive. It's important to understand the potential impact of prescription drug ad changes on JNJ's revenue.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.25)
*   **Target Price:**
    *   Average: 177.47
    *   High: 200.00
    *   Low: 155.00
*   **Recent Rating Changes:** No changes listed.

**Analysis:**  Analysts generally have a "Buy" rating on JNJ. However, the average target price is slightly *below* the current price, suggesting limited upside potential. The range of target prices is wide, indicating differing opinions on JNJ's future performance.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출      |
| :----------- | :----- | :-------- |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2025-07-24 | 1.95 | 22.45 B$ |

**Analysis:** EPS and revenue have fluctuated. The most recent quarter (2025-07-24) shows solid revenue but a lower EPS compared to the previous quarter.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue  | Profit Margin |
| :----------- | :------- | :------------ |
| 2025-06-30 | $23.74B | 67.87%        |
| 2025-03-31 | $21.89B | 66.40%        |
| 2024-12-31 | $22.52B | 68.35%        |
| 2024-09-30 | $22.47B | 69.01%        |
| 2024-06-30 | $22.45B | 69.40%        |

Capital and Profitability:

| Quarter      | Equity   | ROE    |
| :----------- | :------- | :----- |
| 2025-06-30 | $78.47B | 7.06%  |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80%  |
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |

**Analysis:** Revenue has been relatively stable, with a slight increase in the most recent quarter. Profit margins are consistently high. Equity has generally increased, and ROE has fluctuated significantly.

**7. Overall Analysis**

Johnson & Johnson's recent performance has been weak relative to the S&P 500. While analysts maintain a "Buy" rating, the average target price suggests limited upside.  The technical indicators are mixed, with bearish signals from PPO and negative divergence trends. The news flow contains both positive and negative elements. The expected return is extremely negative, raising serious concerns. Revenue and profit margins remain strong, but ROE has been volatile. Overall, the data suggests caution regarding JNJ at this time. Further investigation is needed to determine the cause of the negative expected return and the potential impact of regulatory changes on prescription drug advertising.
